GSK's (GSK) majority-owned ViiV Healthcare said Monday it extended its voluntary licensing agreement with the Medicines Patent Pool to cover the use of cabotegravir in a long-acting HIV treatment regimen.
The updated agreement allows existing licensees, including Aurobindo, Cipla and Viatris (VTRS), to develop, manufacture, and supply generic long-acting injectable cabotegravir for use with rilpivirine to treat HIV-1 in patients aged 12 and older weighing at least 35 kilograms, subject to regulatory approvals.
The expanded license follows updated World Health Organization guidance recommending long-acting injectable cabotegravir and rilpivirine as a treatment option.
It builds on an existing agreement covering the use of cabotegravir in HIV pre-exposure prophylaxis and is intended to broaden access in 133 countries, including all least-developed, low-income and lower middle-income countries, as well as Sub-Saharan Africa and markets where ViiV holds no cabotegravir patents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.